HER2‐positive breast cancer brain metastasis: A new and exciting landscape

BACKGROUND: Brain metastases (BrM) incidence is 25% to 50% in women with advanced human epidermal growth factor receptor 2 (HER2)‐positive breast cancer. Radiation and surgery are currently the main local treatment approaches for central nervous system (CNS) metastases. Systemic anti‐HER2 therapy fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Zimmer, Alexandra S., Van Swearingen, Amanda E. D., Anders, Carey K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9124511/
https://www.ncbi.nlm.nih.gov/pubmed/32881421
http://dx.doi.org/10.1002/cnr2.1274

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9124511/
https://www.ncbi.nlm.nih.gov/pubmed/32881421
http://dx.doi.org/10.1002/cnr2.1274

Ejemplares similares